All enrolled patients who received no less than just one dose of zosuquidar or placebo all through induction were being monitored for your prevalence of adverse events (439 people, 219 on zosuquidar and 210 on placebo). The most typical adverse activities had been associated with the duration of extended and https://pf-480056711098.goabroadblog.com/27653812/the-definitive-guide-to-dup-697